DE:6BG Stock Latest News
Company AnnouncementsLytix Biopharma Grants Over 1 Million Share Options to Bolster Talent Retention1M ago6BG
Company AnnouncementsLytix Biopharma Chair Boosts Stake With Insider Share Purchase1M ago6BG
Company AnnouncementsLytix Biopharma Secures FDA Backing for Ruxotemitide Registrational Melanoma Study2M ago6BG
Company AnnouncementsLytix Biopharma Wins FDA Backing for Phase III Melanoma Trial of Ruxotemitide2M ago6BG- Company AnnouncementsLytix Biopharma Backs New Phase II Melanoma Trial Testing Ruxotemitide with Dual Checkpoint Therapy2M ago6BG
Company AnnouncementsLytix Biopharma Sets Date for Q2 2026 Results and Investor Webcast2M ago6BGCompany AnnouncementsLytix Biopharma hires veteran dealmaker as Chief Business Officer to drive oncology partnerships2M ago6BG
Company AnnouncementsLytix Biopharma Grants 1.23 Million Share Options to Strengthen Executive Incentives3M ago6BG
Company AnnouncementsLytix Biopharma’s Ruxotemitide Combo Shows Promise in Tough Cancers at ASCO 20264M ago6BG
Company AnnouncementsLytix Biopharma Advances Ruxotemitide Program as Q1 2026 Results Underscore Oncology Focus5M ago6BG
Company AnnouncementsLytix Biopharma to Present Q1 2026 Results in Investor Webcast5M ago6BG
Company AnnouncementsLytix Biopharma Highlights New Phase II Data Suggesting Systemic Immune Effects of Cancer Drug5M ago6BG
Company AnnouncementsLytix Biopharma’s Lead Cancer Therapy Highlighted in ASCO 2026 Combination Study6M ago6BGCompany AnnouncementsLytix Biopharma Posts Durable Phase II Responses for Ruxotemitide Combo in Refractory Melanoma6M ago6BG
- Company AnnouncementsLytix Biopharma Overhauls Board and Renews Capital Mandate at AGM6M ago6BG
Company AnnouncementsLytix Biopharma Grants Share Options to Board Member Under Incentive Plan6M ago6BG
Company AnnouncementsLytix Biopharma Appoints New COO to Drive Next Growth Phase6M ago6BG
Company AnnouncementsLytix Biopharma Calls April AGM and Proposes No 2025 Dividend7M ago6BG
Company AnnouncementsLytix Biopharma Marks Pivotal 2025 With Strong Melanoma Data and Capital Raise7M ago6BGCompany AnnouncementsLytix to Unveil Final Phase II Melanoma Data on Ruxotemitide at AACR 20267M ago6BG
Company AnnouncementsLytix Biopharma Registers Share Capital Increase After NOK 16.3 Million Offering8M ago6BG